Ionovol

Magnesium Chloride Hexahydrate, Potassium Chloride, Sodium Chloride and Sodium Acetate Trihydrate, the active ingredient in Ionovol, is an IV electrolyte solution presented as a solution for injection for intravenous use. It restores electrolyte balance and plasma volume in patients requiring fluid and electrolyte therapy.

GNH USA supplies Ionovol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Ionovol acts on the body’s fluid and electrolyte balance to correct deficiencies and support circulatory volume.

Electrolyte replacement: restores deficient magnesium, potassium, sodium and acetate ions in patients with losses due to surgery, diarrhea or chronic disease. Fluid resuscitation: expands intravascular volume in hypovolemic patients to improve perfusion. Treatment of hypomagnesemia: supplies magnesium to correct low serum magnesium levels. Treatment of hypokalemia: provides potassium to normalize serum potassium. Treatment of hyponatremia: delivers sodium to raise low serum sodium concentrations.

Ionovol may be associated with a range of adverse reactions.

Common Side Effects: - Infusion site irritation or pain. - Mild hypermagnesemia presenting as flushing or nausea. - Mild hyperkalemia causing transient muscle weakness. - Nausea or vomiting. - Headache. - Dizziness.

Serious or Rare Side Effects: - Severe hypermagnesemia leading to respiratory depression or cardiac arrest. - Severe hyperkalemia causing life‑threatening arrhythmias. - Anaphylactic or severe allergic reaction. - Cardiac arrhythmia unrelated to electrolyte excess. - Metabolic acidosis from acetate accumulation. - Hypotension due to rapid infusion.

Before initiating therapy, clinicians should evaluate the patient’s baseline electrolyte status and renal function.

Assess electrolyte levels: verify serum magnesium, potassium, sodium and acetate before and during treatment. Monitor cardiac function: observe ECG for arrhythmias, especially in patients with cardiac disease. Adjust dose in renal impairment: reduce infusion rate or volume in patients with reduced renal clearance. Use caution in heart block: avoid rapid infusion that may exacerbate conduction abnormalities. Avoid rapid infusion: administer over the recommended period to prevent circulatory overload. Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture and direct light.

Ionovol can interact with several medications and solutions.

Major Interactions (Avoid): - Concurrent IV electrolyte solutions: risk of electrolyte overload. - Calcium‑containing solutions: potential precipitation of calcium‑magnesium salts. - Loop diuretics: increase loss of administered electrolytes. - ACE inhibitors or ARBs: heightened risk of hyperkalemia. - Sodium bicarbonate: may alter acetate metabolism.

Moderate Interactions (Monitor Closely): - NSAIDs: may impair renal function affecting electrolyte clearance. - Digoxin: electrolyte shifts can modify digoxin toxicity. - Anticoagulants: fluid shifts may affect bleeding risk. - Beta‑blockers: combined hypotensive effects. - Corticosteroids: may cause fluid retention and alter electrolyte balance.